Free Trial
NASDAQ:CVKD

Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis

Cadrenal Therapeutics logo
$17.73 +1.17 (+7.07%)
(As of 11:22 AM ET)

About Cadrenal Therapeutics Stock (NASDAQ:CVKD)

Key Stats

Today's Range
$16.90
$18.00
50-Day Range
$7.06
$17.89
52-Week Range
$5.40
$32.55
Volume
28,750 shs
Average Volume
29,870 shs
Market Capitalization
$18.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.00
Consensus Rating
Buy

Company Overview

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Cadrenal Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
21st Percentile Overall Score

CVKD MarketRank™: 

Cadrenal Therapeutics scored higher than 21% of companies evaluated by MarketBeat, and ranked 896th out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cadrenal Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Cadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Cadrenal Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($7.92) to ($3.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cadrenal Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cadrenal Therapeutics is -2.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cadrenal Therapeutics has a P/B Ratio of 5.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Cadrenal Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.06% of the float of Cadrenal Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cadrenal Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cadrenal Therapeutics has recently increased by 65.27%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Cadrenal Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Cadrenal Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.06% of the float of Cadrenal Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Cadrenal Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cadrenal Therapeutics has recently increased by 65.27%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Cadrenal Therapeutics has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Cadrenal Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    7 people have searched for CVKD on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cadrenal Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    48.62% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.92% of the stock of Cadrenal Therapeutics is held by institutions.

  • Read more about Cadrenal Therapeutics' insider trading history.
Receive CVKD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CVKD Stock News Headlines

Analysts Offer Predictions for CVKD Q1 Earnings
Cadrenal Therapeutics (NASDAQ:CVKD) Price Target Raised to $32.00
Post-Election Bitcoin Warning
According to the man who has called nearly every bubble of the last 25 years, Bitcoin owners should get ready to pay back all the gains they've seen the last few months...
Cadrenal Therapeutics Advances Tecarfarin Development
See More Headlines

CVKD Stock Analysis - Frequently Asked Questions

Cadrenal Therapeutics' stock was trading at $7.1850 at the beginning of 2024. Since then, CVKD shares have increased by 146.8% and is now trading at $17.73.
View the best growth stocks for 2024 here
.

Cadrenal Therapeutics (CVKD) raised $7 million in an initial public offering (IPO) on Friday, January 20th 2023. The company issued 1,400,000 shares at a price of $5.00 per share.

Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cadrenal Therapeutics investors own include Clean Energy Fuels (CLNE), Paycom Software (PAYC), uniQure (QURE), AbCellera Biologics (ABCL), Grayscale Ethereum Trust (ETH) (ETHE), Mitsubishi UFJ Financial Group (MUFG) and Oatly Group (OTLY).

Company Calendar

Today
11/14/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/10/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CVKD
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.00
High Stock Price Target
$32.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+8.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-8,360,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.20 per share

Miscellaneous

Free Float
549,000
Market Cap
$17.72 million
Optionable
Not Optionable
Beta
1.52
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:CVKD) was last updated on 11/14/2024 by MarketBeat.com Staff
From Our Partners